Nutrient biomarkers are measurable substances in the body—such as levels of vitamins, minerals, or metabolites in biological tissue that indicate a person’s nutritional status. AG1 Next Gen was studied in a 12-week, triple-blind, randomized, placebo-controlled clinical trial with 105 healthy adults aged 20-59, all following a Standard American Diet. The study aimed to assess how daily intake of AG1 Next Gen influenced nutrient biomarkers, microbiome changes, and markers related to overall well-being. The study used a parallel design to compare outcomes between the AG1 Next Gen and placebo groups.

A nutrient gap is the difference between the amount of a specific nutrient a person needs and the amount they are actually getting from their diet. The impact of AG1 Next Gen on filling common nutrient gaps was evaluated in four clinical studies that varied in population, design, and duration:

1. A triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
2. A double-blind, randomized, placebo-controlled 2-week cross-over clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.
3. A double-blind, randomized, placebo-controlled 2-week cross-over clinical trial assessing nutrient gaps and microbiome assessments of 24 healthy adults with occasional GI distress ages 26-59.
4. A double-blind, randomized, placebo-controlled cross-over clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.

Studying changes in the gut microbiome in response to supplementation provides important insight into how these interventions can influence gut health and broader physiological processes. The impact of AG1 Next Gen on gut health and microbiome was evaluated in the three clinical studies below.

1. A triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
2. A double-blind, randomized, placebo-controlled 2-week cross-over clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.
3. A double-blind, randomized, placebo-controlled 2-week cross-over clinical trial assessing nutrient gaps and microbiome assessments of 24 healthy adults with occasional GI distress ages 26-59.

Bioavailability is the extent to which your body can absorb and use a given nutrient. Factors like dosage, formulation, and your individual physiology all play a role — and they directly impact how effectively a nutrient supports key functions in the body. To better understand how key nutrients in AG1 Next Gen are absorbed after consumption, we designed a pharmacokinetic study using a double-blind, randomized, placebo-controlled cross-over clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.